ClinicalTrials.gg
CompletedNCT01800630Updated Jul 8, 2019

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

A Phase 1 interventional study of Gemcitabine HCl Oral Formulation in Advanced Solid Malignancies and Malignant Lymphomas, sponsored by InnoPharmax Inc.. Completed at 3 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by InnoPharmax Inc. · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Lymphoma with a site in Taiwan — 11 open to participants now, 18 under way, 7 of them phase 3. Lymphoma · Taiwan.

Enrollment
28th of 33
37 · median 80
Started
2013
with 2 others
Phase 1
9 of 40
3 open now
Registered
10th of 40
by date

Among the 40 studies in Lymphoma with a site in Taiwan, this one is the 28th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 1, and was the 10th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

11 of the 40 studies in Lymphoma with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Lymphoma with a site in Taiwan, or all of them as a file.
02

Study summary

Open-label Phase 1 sequential dose-escalation study of 10 increasing doses (3 to 6 patients each)to determine and characterize the DLTs and MTD of gemcitabine HCl oral formulation (D07001-F4). Patients will be assigned to receive oral D07001-F4 on Days 1, 3, 5, 8, 10, and 12 of 4 21-day cycles each to further characterize safety and tolerability.

03

Conditions studied

  • Advanced Solid Malignancies
  • Malignant Lymphomas

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 20 years and older
  • Signed and dated form
  • Patients with advanced solid and malignant lymphomas with histological or pathologic confirmation who have failed standard therapies or for which no standard therapy exists
  • Both measurable and non- allowed (measurable disease per , version 1.1, or Revised Response Criteria for Malignant Lymphoma [Cheson criteria])
  • World Health Organization (WHO) performance status 0 to 2
  • At least 28 days have elapsed (before screening) since the patient's prior systemic therapy, radiotherapy, or any major surgery (excluding diagnostic or venous access device placement)
  • Patient has

    • (ANC) ≥ 1500 cells/mm³
    • count ≥ 75,000 cells/mm³
    • ≥ 9 g/dL.
  • Patient has adequate liver function, demonstrated by:

    • (AST) and alanine transaminase (ALT) ≤ 2.5*the (ULN) (≤ 5.0*ULN in case of liver )
    • Total ≤ 1.5 mg/dL (unless due to Gilbert's syndrome)
    • Albumin ≥ 2.5 g/dL
    • (INR) \< 1.5
  • Patient has adequate renal function:

    • Serum creatinine ≤ 1.5*ULN.
  • Patient has a > 12 weeks.
  • If a woman of , patient has a negative pregnancy test and is not breast feeding.
  • If a woman of child-bearing potential, patient is using a medically acceptable form as two barrier methods (e.g., combination of condom, diaphragm, intrauterine device), hormonal (estrogen or progesterone agents) or one barrier method in combination with spermicide. Birth control is required 1 month prior to screening, for the duration of their study participation, and for 1 month after the end of the study; female partners of male patients will also adhere to similar birth control methods
  • Patient is willing to comply with protocol-required visit schedule and visit requirements

Exclusion criteria

Exclusion Criteria:

  • Patient is receiving full-dose (therapeutic) anticoagulation therapy.
  • Patient is intolerant or allergic or has a known to gemcitabine
  • Patient has cardiovascular disease (for example: uncontrolled hypertension, unstable angina, congestive heart failure, or Grade 2 or greater).
  • Patient has uncontrolled serious cardiac arrhythmia.
  • Patient has known or any .
  • Patient has any unresolved toxicity (>Grade 1) from previous anticancer therapy with the exception of renal and liver function which are required to be in the range as described in inclusion criteria and peripheral neuropathy acceptable if resolved to at least grade 2.
  • Patient has received radiotherapy of more than 10 Gy within 6 months of screening.
  • Patient has a history of drug or alcohol abuse within last year.
  • Patient has documented cerebrovascular disease.
  • Patient has a seizure disorder not controlled on medication (based on decision of Investigator).
  • Patient received an agent within 28 days of screening
  • Patient received systemic treatment for infection within 14 days of screening.
  • Patient has known (HIV) infection.
  • Patient has virus (HBV) and/or virus (HCV) infection in medical history.
  • Patient has received yellow fever vaccine and other within the last 4 weeks
  • Patient has any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in a clinical trial.
  • Patients have gastrointestinal disease/prior surgery that may interfere with adequate oral therapy absorption
  • Patients after stem cell transplantation
  • Patients with less than 12 months from autologous stem cell transplantation
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Gemcitabine HCl Oral Formulation (D07001-F4)

    Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.

    Drug: Gemcitabine HCl Oral Formulation

Interventions

  • DrugGemcitabine HCl Oral Formulation

    Also known as: D07001-F4

06

What researchers measure

Primary outcomes

  1. To determine MTD and DLT of Gemcitabine Oral formulation

    MTD will be determined by study structure and DLT will be determined by definition

    Time frame: During the 21-day cycle 1 treatment

Secondary outcomes

  1. AE/SAE incidences

    AEs will be assessed via the CTCAE version 4.03

    Time frame: Throughout treatment and 30-day follow-up (estimated average of 5 months)

  2. Changes from baseline in clinical laboratory test (hematology, biochemistry, coagulation factors and urinalysis) results, vital sign measurements, physical examination findings, and ECG and 2D echocardiogram/multiple-gated acquisition (MUGA) scan results

    Time frame: Throughout treatment and 30-day follow-up (estimated average of 5 months)

  3. characterize the PK of D07001-F4

    Time frame: cycle 0 and cycle 1 (Day -7~Day 19)

  4. ORR(Objective Response Rate) and tumor response

    Time frame: After cycle 2 and cycle 4 treatments (estimated average of 2 months and 4 months)

07

Study locations

3 sites
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Nov 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2013
First posted
Feb 28, 2013
Start
Apr 2013
Primary completionActual
Nov 2015
CompletionActual
Mar 2016
Last update
Jul 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01800630
Lead sponsor
InnoPharmax Inc.
Responsible party
Sponsor
First posted
Feb 28, 2013
Start date
Apr 2013
Primary completion
Nov 2015
Completion
Mar 2016
Last update
Jul 8, 2019

Study contacts

Chia-Chi Lin, MD
principal investigator · National Taiwan University Hospital
Wu-Chou Su, MD
principal investigator · National Cheng-Kung University Hospital
Yee Chao, MD
principal investigator · Taipei Veterans General Hospital, Taiwan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion